Helen Torley sold $4.4M of HALO
PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC.. 60,000 shares at an average of $74.08, traded Sep 2, 2025, filed Sep 4, 2025.
Score components
- +25RoleCEO
- +25Trade size$4.4M at market
- 0Share of holdings soldSold 8.0% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.0%, 3m -14.2%, 6m -8.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-023720, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 2, 2025 | MOption exercise Common Stock10b5-1 | +20,000 | $8.11 | $162k | 753,719 | Sep 4, 2025 |
| Sep 2, 2025 | SOpen-market sale Common Stock10b5-1 | -300 | $72.49 | $22k | 753,419 | Sep 4, 2025 |
| Sep 2, 2025 | SOpen-market sale Common Stock10b5-1 | -16,288 | $73.70 | $1.2M | 737,131 | Sep 4, 2025 |
| Sep 2, 2025 | SOpen-market sale Common Stock10b5-1 | -3,412 | $74.15 | $253k | 733,719 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Common Stock10b5-1 | +20,000 | $8.11 | $162k | 753,719 | Sep 4, 2025 |
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -9,500 | $74.22 | $705k | 744,219 | Sep 4, 2025 |
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -10,500 | $74.63 | $784k | 733,719 | Sep 4, 2025 |
| Sep 4, 2025 | MOption exercise Common Stock10b5-1 | +20,000 | $8.11 | $162k | 753,719 | Sep 4, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stock10b5-1 | -9,900 | $73.54 | $728k | 743,819 | Sep 4, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stock10b5-1 | -7,800 | $74.33 | $580k | 736,019 | Sep 4, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stock10b5-1 | -2,300 | $75.22 | $173k | 733,719 | Sep 4, 2025 |
| Sep 2, 2025 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -20,000 | $8.11 | $162k | 176,569 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -20,000 | $8.11 | $162k | 156,569 | Sep 4, 2025 |
| Sep 4, 2025 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -20,000 | $8.11 | $162k | 136,569 | Sep 4, 2025 |
Related signals
Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.6M 60,000 shares | -8% | |
| 22Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $568k 5,230 shares | -9% | |
| 33Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $2.0M 18,996 shares | -24% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.4M 60,000 shares | -8% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.3M 60,000 shares | -8% | |
| 14Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $167k 1,626 shares | -4% | |
| 16Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $153k 1,923 shares | -0% | |
| 20Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $125k 1,625 shares | -4% | |
| 24Weak | HALOZYME THERAPEUTICS, INC. | Mahesh Krishnan director | $548k 7,304 shares | -34% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $3.4M 50,000 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.